Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07811271 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

Name: Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers — clinical trial record (NCT07811271)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorBeOne Medicines

Started2026-10

View on ClinicalTrials.gov ↗

BeOne Medicines

59 trials monitored

See 7 trials at risk

Ovarian Cancer

1,239 trials monitored

See 74 trials at risk

The purpose of this study is to evaluate the safety and efficacy of BG-C9074 with bevacizumab (Arm A) versus bevacizumab monotherapy (Arm B) in adults with epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after firstline platinum-based chemotherapy plus bevacizumab.

Trial Details

NCT Number	NCT07811271
Lead Sponsor	BeOne Medicines Collaborators: GOG Foundation, Latin American Cooperative Oncology Group (LACOG), European Network of Gynaecological Oncological Trial Groups (ENGOT), Asia-Pacific Gynecologic Oncology Trials Group
Conditions	Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Enrollment	600 participants
Start Date	2026-10
Primary Completion	2029-11-30 (estimated)
Study Completion	2033-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-09-10